These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 23943023)

  • 1. Rational study endpoint(s) for preoperative trials in pancreatic cancer: pathologic response rate, margin negative resection, overall survival or 'all of the above'?
    Varadhachary GR; Evans DB
    Ann Surg Oncol; 2013 Nov; 20(12):3712-4. PubMed ID: 23943023
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma.
    Cloyd JM; Crane CH; Koay EJ; Das P; Krishnan S; Prakash L; Snyder RA; Varadhachary GR; Wolff RA; Javle M; Shroff RT; Fogelman D; Overman M; Wang H; Maitra A; Lee JE; Fleming JB; Katz MH
    Cancer; 2016 Sep; 122(17):2671-9. PubMed ID: 27243381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study.
    Labori KJ; Katz MH; Tzeng CW; Bjørnbeth BA; Cvancarova M; Edwin B; Kure EH; Eide TJ; Dueland S; Buanes T; Gladhaug IP
    Acta Oncol; 2016; 55(3):265-77. PubMed ID: 26213211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer.
    Roland CL; Yang AD; Katz MH; Chatterjee D; Wang H; Lin H; Vauthey JN; Pisters PW; Varadhachary GR; Wolff RA; Crane CH; Lee JE; Fleming JB
    Ann Surg Oncol; 2015 Apr; 22(4):1168-75. PubMed ID: 25352267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different clinical presentations of metachronous pulmonary metastases after resection of pancreatic ductal adenocarcinoma: Retrospective study and review of the literature.
    Lovecek M; Skalicky P; Chudacek J; Szkorupa M; Svebisova H; Lemstrova R; Ehrmann J; Melichar B; Yogeswara T; Klos D; Vrba R; Havlik R; Mohelnikova-Duchonova B
    World J Gastroenterol; 2017 Sep; 23(35):6420-6428. PubMed ID: 29085191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The promise of modern radiotherapy in resected pancreatic adenocarcinoma: a response to Bekaii-Saab et al.
    Narang AK; Herman JM
    Ann Surg Oncol; 2014 Apr; 21(4):1064-6. PubMed ID: 24522986
    [No Abstract]   [Full Text] [Related]  

  • 7. The indolent nature of pulmonary metastases from ductal adenocarcinoma of the pancreas.
    Downs-Canner S; Zenati M; Boone BA; Varley PR; Steve J; Hogg ME; Zureikat A; Zeh HJ; Lee KK
    J Surg Oncol; 2015 Jul; 112(1):80-5. PubMed ID: 26153355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of pathologic response to preoperative therapy in pancreatic cancer.
    Chun YS; Cooper HS; Cohen SJ; Konski A; Burtness B; Denlinger CS; Astsaturov I; Hall MJ; Hoffman JP
    Ann Surg Oncol; 2011 Dec; 18(13):3601-7. PubMed ID: 21947697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survival.
    Massucco P; Capussotti L; Magnino A; Sperti E; Gatti M; Muratore A; Sgotto E; Gabriele P; Aglietta M
    Ann Surg Oncol; 2006 Sep; 13(9):1201-8. PubMed ID: 16955382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multidisciplinary management of locally advanced pancreatic ductal adenocarcinoma.
    Alemi F; Alseidi A; Scott Helton W; Rocha FG
    Curr Probl Surg; 2015 Sep; 52(9):362-98. PubMed ID: 26363649
    [No Abstract]   [Full Text] [Related]  

  • 11. Locally advanced anaplastic pancreatic adenocarcinoma with initial response to FOLFIRINOX and rapid progression after five months.
    Shinagare AB; Ramaiya NH; Bellizzi AM; Mayer RJ
    Pancreatology; 2012; 12(1):35-8. PubMed ID: 22487471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of perioperative red blood cell transfusion on disease recurrence and survival after pancreaticoduodenectomy for ductal adenocarcinoma.
    Kneuertz PJ; Patel SH; Chu CK; Maithel SK; Sarmiento JM; Delman KA; Staley CA; Kooby DA
    Ann Surg Oncol; 2011 May; 18(5):1327-34. PubMed ID: 21369744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathologic Major Response After FOLFIRINOX is Prognostic for Patients Secondary Resected for Borderline or Locally Advanced Pancreatic Adenocarcinoma: An AGEO-FRENCH, Prospective, Multicentric Cohort.
    Pietrasz D; Marthey L; Wagner M; Blanc JF; Laurent C; Turrini O; Raoul JL; Terrebonne E; Hentic O; Trouilloud I; Coriat R; Regenet N; Innominato P; Taieb J; Cunha AS; Bachet JB
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1196-205. PubMed ID: 26271395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Locally Advanced Pancreatic Ductal Adenocarcinoma.
    Loehrer AP; Ferrone CR
    Dig Surg; 2016; 33(4):343-50. PubMed ID: 27216011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rational combinations of immunotherapy for pancreatic ductal adenocarcinoma.
    Blair AB; Zheng L
    Chin Clin Oncol; 2017 Jun; 6(3):31. PubMed ID: 28705008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma.
    Silvestris N; Longo V; Cellini F; Reni M; Bittoni A; Cataldo I; Partelli S; Falconi M; Scarpa A; Brunetti O; Lorusso V; Santini D; Morganti A; Valentini V; Cascinu S
    Crit Rev Oncol Hematol; 2016 Feb; 98():309-24. PubMed ID: 26653573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pancreatic adenocarcinoma: treating a systemic disease with systemic therapy.
    Sohal DP; Walsh RM; Ramanathan RK; Khorana AA
    J Natl Cancer Inst; 2014 Mar; 106(3):dju011. PubMed ID: 24563516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with better prognosis.
    Wang H; Zhao Q
    Ann Diagn Pathol; 2012 Oct; 16(5):427. PubMed ID: 22561135
    [No Abstract]   [Full Text] [Related]  

  • 19. Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma means no residual tumor: no need to assess "viability".
    Krasinskas AM
    Ann Diagn Pathol; 2012 Apr; 16(2):158-9. PubMed ID: 22405469
    [No Abstract]   [Full Text] [Related]  

  • 20. Pancreatic cancer. A multidisciplinary approach.
    López Martín A; Carballo Alvarez LF
    Rev Esp Enferm Dig; 2011 Jan; 103(1):1-4. PubMed ID: 21341930
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.